Background

Multiple sclerosis (MS) is a representative chronic autoimmune disease where the immune system attacks the myelin of the central nervous system, causing nerve damage. Based on large-scale epidemiological studies, it has been consistently suggested that Epstein-Barr virus (EBV) infection is an essential prerequisite for the onset of the disease. However, the molecular biological causal relationship explaining why this common herpesvirus, which most adults are infected with at least once in their lifetime, causes destructive neuroinflammation only in specific patient groups has not been fully elucidated.

Existing studies have mostly remained cross-sectional, comparing serum antibody titers before and after disease onset or observing post-mortem brain tissue. This approach demonstrated limitations in real-time tracking of the dynamic changes associated with the precise timing of reactivation of latent viruses within the body that trigger relapses. Furthermore, it failed to clearly explain how hundreds of genetic risk variants identified through genome-wide association studies interact with the actual state of viral infection to lead to acute neurological deterioration.

Key Findings

Researchers performed a precise analysis of longitudinal follow-up blood samples from MS patients to track molecular transcriptomic changes occurring within B cells. The analysis captured a significant surge in the expression of genes related to the reactivation of latent EBV within B cells immediately before patients experienced acute neurological symptom exacerbation. This effectively captured at the molecular level that viral activation signals, which prepare for replication after breaking dormancy, act as a precursor to disease relapse.

In particular, the researchers focused on the movement of Epstein-Barr virus nuclear antigen 2 (EBNA-2), a key transcriptional regulatory protein expressed by the virus. EBNA-2 is well known as a factor that binds to the host cell's transcriptional complex to disrupt gene expression. Data analysis revealed that the set of target genes directly bound and upregulated by EBNA-2 significantly overlaps with the known genetic risk gene set for multiple sclerosis.

Just before an actual clinical seizure occurs, the transcript levels of EBNA-2 target risk genes in the patient's B cells rise sharply compared to baseline. When the virus reactivates in the B cells of patients with an inherited immunogenetic susceptibility, the EBNA-2 protein intensively activates the host's autoimmune risk gene switches, triggering a systemic inflammatory response. The molecular mechanism, where the combination of viral reactivation and host genetic risk factors drives disease relapse, has been clearly linked for the first time.

Significance and Outlook

This discovery provides an opportunity to fundamentally shift the paradigm of multiple sclerosis management. The fact that viral genes and EBNA-2 expression rise before an acute relapse serves as direct evidence for the development of early warning biomarkers. If these transcript levels can be monitored through regular blood tests, preemptive therapeutic intervention becomes possible before irreversible nerve damage occurs.

In terms of therapeutic strategies, diversification of the target landscape is expected. The widely used broad B-cell depletion antibody therapies carry the side effect of increasing susceptibility to infection by suppressing the patient's overall humoral immunity. In the future, antivirals that inhibit viral reactivation itself or precision small molecule compounds that block the binding between EBNA-2 and host chromatin are likely to emerge as new therapeutic alternatives with minimized side effects.

A cautious approach is also required. A technical challenge remains in how rapidly and in a standardized manner trace amounts of viral transcripts in B cells can be detected in clinical settings. It is also difficult to rule out the possibility of variations in expression patterns depending on the combination of genetic variants and viral strains held by each patient. Large-scale follow-up studies to verify the reproducibility of biomarkers across diverse ethnicities and disease stages must follow.